• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经典型霍奇金淋巴瘤中T细胞和NK细胞的知识演进:对免疫微环境中新型亚群的见解

The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment.

作者信息

Ferrarini Isacco, Rigo Antonella, Visco Carlo, Krampera Mauro, Vinante Fabrizio

机构信息

Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy.

Cancer Research and Cell Biology Laboratory, Department of Medicine, University of Verona, 37134 Verona, Italy.

出版信息

Cancers (Basel). 2020 Dec 14;12(12):3757. doi: 10.3390/cancers12123757.

DOI:10.3390/cancers12123757
PMID:33327433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7764890/
Abstract

Classic Hodgkin lymphoma (cHL) is a unique lymphoid neoplasm characterized by extensive immune infiltrates surrounding rare malignant Hodgkin Reed-Sternberg (HRS) cells. Different subsets of T and NK cells have long been recognized in the cHL microenvironment, yet their distinct contribution to disease pathogenesis has remained enigmatic. Very recently, novel platforms for high dimensional analysis of immune cells, such as single-cell RNA sequencing and mass cytometry, have revealed unanticipated insights into the composition of T- and NK-cell compartments in cHL. Advances in imaging techniques have better defined specific T-helper subpopulations physically interacting with neoplastic cells. In addition, the identification of novel cytotoxic subsets with an exhausted phenotype, typically enriched in cHL milieu, is shedding light on previously unrecognized immune evasion mechanisms. This review examines the immunological features and the functional properties of T and NK subsets recently identified in the cHL microenvironment, highlighting their pathological interplay with HRS cells. We also discuss how this knowledge can be exploited to predict response to immunotherapy and to design novel strategies to improve PD-1 blockade efficacy.

摘要

经典型霍奇金淋巴瘤(cHL)是一种独特的淋巴样肿瘤,其特征是在罕见的恶性霍奇金-里德-斯腾伯格(HRS)细胞周围有广泛的免疫浸润。长期以来,人们在cHL微环境中已识别出不同的T细胞和自然杀伤(NK)细胞亚群,但它们对疾病发病机制的独特贡献仍不明确。最近,诸如单细胞RNA测序和质谱细胞术等用于免疫细胞高维分析的新平台,揭示了cHL中T细胞和NK细胞区室组成方面意想不到的见解。成像技术的进步更好地界定了与肿瘤细胞发生物理相互作用的特定辅助性T细胞亚群。此外,对通常在cHL环境中富集的具有耗竭表型的新型细胞毒性亚群的识别,正在揭示此前未被认识的免疫逃逸机制。本综述探讨了最近在cHL微环境中识别出的T细胞和NK细胞亚群的免疫学特征及功能特性,强调了它们与HRS细胞的病理相互作用。我们还讨论了如何利用这些知识来预测免疫治疗反应,并设计新策略以提高程序性死亡蛋白1(PD-1)阻断疗法的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c6/7764890/645c441d4306/cancers-12-03757-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c6/7764890/edd03c2b97f2/cancers-12-03757-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c6/7764890/98001dd2563b/cancers-12-03757-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c6/7764890/89409f43a1ff/cancers-12-03757-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c6/7764890/645c441d4306/cancers-12-03757-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c6/7764890/edd03c2b97f2/cancers-12-03757-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c6/7764890/98001dd2563b/cancers-12-03757-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c6/7764890/89409f43a1ff/cancers-12-03757-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c6/7764890/645c441d4306/cancers-12-03757-g004.jpg

相似文献

1
The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment.经典型霍奇金淋巴瘤中T细胞和NK细胞的知识演进:对免疫微环境中新型亚群的见解
Cancers (Basel). 2020 Dec 14;12(12):3757. doi: 10.3390/cancers12123757.
2
Mass cytometry of Hodgkin lymphoma reveals a CD4 regulatory T-cell-rich and exhausted T-effector microenvironment.霍奇金淋巴瘤的液滴式细胞术分析显示富含 CD4 调节性 T 细胞和耗竭的 T 效应细胞的微环境。
Blood. 2018 Aug 23;132(8):825-836. doi: 10.1182/blood-2018-04-843714. Epub 2018 Jun 7.
3
Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma.经典霍奇金淋巴瘤中的复杂免疫逃逸策略。
Cancer Immunol Res. 2017 Dec;5(12):1122-1132. doi: 10.1158/2326-6066.CIR-17-0325. Epub 2017 Oct 25.
4
An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma.经典型霍奇金淋巴瘤中单核细胞-巨噬细胞的最新描述
Front Oncol. 2023 Feb 24;13:1149616. doi: 10.3389/fonc.2023.1149616. eCollection 2023.
5
Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications.解析经典型霍奇金淋巴瘤的免疫微环境:对预后和治疗的意义
Biology (Basel). 2023 Jun 15;12(6):862. doi: 10.3390/biology12060862.
6
Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.全切片图像分析显示,肿瘤微环境中霍奇金-里德-斯腾伯格细胞含量高、T淋巴细胞含量低,可作为接受ABVD治疗的经典型霍奇金淋巴瘤患者不良预后的预测指标。
Front Oncol. 2022 Oct 20;12:1000762. doi: 10.3389/fonc.2022.1000762. eCollection 2022.
7
The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.EB病毒和HIV感染对霍奇金淋巴瘤发病机制所基于的微环境生态位的影响。
Int J Cancer. 2017 Mar 15;140(6):1233-1245. doi: 10.1002/ijc.30473. Epub 2016 Oct 27.
8
T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses.通过单细胞分析揭示经典霍奇金淋巴瘤中的 T 细胞状态、受体库和功能。
Cancer Immunol Res. 2024 Mar 4;12(3):296-307. doi: 10.1158/2326-6066.CIR-23-0547.
9
Chronic Active Epstein-Barr Virus Infection of T/NK-Cell Type Mimicking Classic Hodgkin Lymphoma: Clinicopathologic and Genetic Features of 8 Cases Supporting a Variant With "Hodgkin/Reed-Sternberg-like" Cells of NK Phenotype.T/NK 细胞型慢性活动性 EBV 感染酷似经典霍奇金淋巴瘤:8 例支持具有“霍奇金/里斯汀伯样”NK 表型细胞的变异型的临床病理和遗传学特征。
Am J Surg Pathol. 2019 Dec;43(12):1611-1621. doi: 10.1097/PAS.0000000000001324.
10
Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells.应对经典型霍奇金淋巴瘤中失调的免疫检查点:微环境与霍奇金/里德-斯腾伯格细胞之间的双向调节
Front Oncol. 2023 May 24;13:1203470. doi: 10.3389/fonc.2023.1203470. eCollection 2023.

引用本文的文献

1
Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma.影响经典霍奇金淋巴瘤结局的免疫和基质转录模式。
Sci Rep. 2024 Jan 6;14(1):710. doi: 10.1038/s41598-024-51376-1.
2
Location, location, location: mapping the lymphoma tumor microenvironment using spatial transcriptomics.位置,位置,还是位置:利用空间转录组学绘制淋巴瘤肿瘤微环境图谱
Front Oncol. 2023 Oct 4;13:1258245. doi: 10.3389/fonc.2023.1258245. eCollection 2023.
3
Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications.

本文引用的文献

1
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.经典型霍奇金淋巴瘤接受抗 PD-1 治疗后出现肿瘤和微环境反应,但无细胞毒性 T 细胞激活。
Blood. 2020 Dec 17;136(25):2851-2863. doi: 10.1182/blood.2020008553.
2
The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma.CD4+ T 细胞在 PD-1 阻断针对 MHC-II 表达肿瘤(如经典霍奇金淋巴瘤)中的关键作用。
Blood Adv. 2020 Sep 8;4(17):4069-4082. doi: 10.1182/bloodadvances.2020002098.
3
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
解析经典型霍奇金淋巴瘤的免疫微环境:对预后和治疗的意义
Biology (Basel). 2023 Jun 15;12(6):862. doi: 10.3390/biology12060862.
4
Misdiagnosis of angioimmunoblastic T‑cell lymphoma: A case report.血管免疫母细胞性T细胞淋巴瘤的误诊:一例报告
Oncol Lett. 2023 Apr 26;25(6):250. doi: 10.3892/ol.2023.13836. eCollection 2023 Jun.
5
An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma.经典型霍奇金淋巴瘤中单核细胞-巨噬细胞的最新描述
Front Oncol. 2023 Feb 24;13:1149616. doi: 10.3389/fonc.2023.1149616. eCollection 2023.
6
Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.霍奇金淋巴瘤:生物学特性与鉴别诊断问题
Diagnostics (Basel). 2022 Jun 20;12(6):1507. doi: 10.3390/diagnostics12061507.
7
The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good.霍奇金淋巴瘤的免疫微环境:化坏消息为好消息。
Cancers (Basel). 2022 Mar 7;14(5):1360. doi: 10.3390/cancers14051360.
伊匹木单抗、纳武单抗和本妥昔单抗联合疗法用于复发或难治性霍奇金淋巴瘤患者:一项开放标签、多中心、1/2期试验的1期结果
Lancet Haematol. 2020 Sep;7(9):e660-e670. doi: 10.1016/S2352-3026(20)30221-0.
4
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma.经典型霍奇金淋巴瘤患者对 PD-1 阻断治疗反应的外周免疫特征。
Nat Med. 2020 Sep;26(9):1468-1479. doi: 10.1038/s41591-020-1006-1. Epub 2020 Aug 10.
5
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.一项 AFM13 联合帕博利珠单抗治疗复发或难治性霍奇金淋巴瘤患者的 1b 期研究。
Blood. 2020 Nov 19;136(21):2401-2409. doi: 10.1182/blood.2019004701.
6
Hodgkin lymphoma.霍奇金淋巴瘤。
Nat Rev Dis Primers. 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6.
7
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.抗 CD30 CAR-T 细胞疗法在复发/难治性霍奇金淋巴瘤中的应用。
J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23.
8
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.一项在复发/难治性淋巴恶性肿瘤患者中进行的双重 PD-1 和 CTLA-4 或 KIR 阻断的 1b 期研究。
Leukemia. 2021 Mar;35(3):777-786. doi: 10.1038/s41375-020-0939-1. Epub 2020 Jun 29.
9
Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.霍奇金淋巴瘤中的玫瑰花结 T 细胞被免疫突触成分 HLA Ⅱ类和 CD58 激活。
Blood. 2020 Nov 19;136(21):2437-2441. doi: 10.1182/blood.2020005546.
10
Aberrant peripheral blood CD4 CD25 FOXP3 regulatory T cells/T helper-17 number is associated with the outcome of patients with lymphoma.异常外周血 CD4 CD25 FOXP3 调节性 T 细胞/T 辅助-17 细胞数量与淋巴瘤患者的预后相关。
Cancer Immunol Immunother. 2020 Sep;69(9):1917-1928. doi: 10.1007/s00262-020-02591-y. Epub 2020 May 8.